Diabetic Macular Edema Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Diabetic Macular Edema Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Future Market Insights forecasts the global diabetic macular edema market to grow from nearly US$ 3,710 Mn in 2017 to over US$ 4,100 Mn by 2027 end. This represents a CAGR of 1.1% over the forecast period of 2017– 2027. North America is projected to be the largest market in terms of value and accounted for the highest revenue share of 51.5% in 2016.

Growing adoption of recently approved Intravitreal implants in North America

Before the launch of Lucentis for DME treatment in 2012, the use of intravitreally injected medications was less common in North America and laser photocoagulation was the primary treatment. However, Avastin and Macugen were being used off-label for diabetic macular edema treatment since 2004. Launch of three new products in 2014 viz. Eylea, Ozurdex and Iluvien, has led to the increased adoption of Intravitreal medications in North America. For instance, according to estimates of the University of Washington, before 2004, 5.75% of DME patients used Intravitreal injections, which increased to 20% by 2013. In 2016, over 70% of DME patients were utilising Intravitreal injections and implants. This sudden increase in the adoption of Intravitreal therapies can be attributed to the launch of low dose high efficacy corticosteroid implants for Intravitreal use. Uptake of Intravitreal implants by new patients as well as by patients previously treated with Intravitreal injections but who do not show any improvement, is expected to push the market for diabetic macular edema in the region.

Growing economic burden of diabetes and related disorders

Diabetic Macular Edema (DME) is a leading cause of blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and DME patients utilise significantly higher healthcare resources than non-DME diabetic patients. As per a survey conducted by the University of Washington, the total yearly median cost for DME patients was reported to be US$ 14,678 and that for non-DME diabetic patients was US$ 6,801 in 2011. Moreover, DME patients have to visit their physicians for at least 30 days per year in contrast to an average of 14 visits per year in the case of non-DME diabetic patients. The growing incidences of diabetes across the globe further increase the burden of DME. According to the International Diabetic Federation (IDF), 382 Mn people worldwide have diabetes and the number is expected to grow to 592 Mn by 2035.

Gaps in making DME a health priority hampering market growth in North America

Although control of diabetes is made a health priority in developed countries such as the U.S., much attention is not given to DME management and diabetes related caregivers tend to focus on the treatment of other diabetic complications. The major reason for this is the lack of effective treatment for DME. Even though anti-VEGF and corticosteroid therapies have changed the treatment paradigm, there exists a gap in patients’ clinical information among clinicians. Furthermore, there exists an error in industry sponsored and independently run clinical trials. For instance, there are approximately 72 independent clinical trials going on for DME treatment, but most of them lack long-term results regarding safety and efficacy on new and combination therapies for diabetic macular edema. These factors are hampering revenue growth of the diabetic macular edema market in North America. Western Europe is expected to be the most lucrative market for diabetic macular edema, with market attractiveness index of 2.7. Major players in the diabetic macular edema market, including Bayer AG and Novartis AG, are focussing on improving the sale of Eylea and Lucentis, respectively, in Europe. Companies are trying to exploit the full market potential and get maximum returns on R&D till patents for their drugs are alive. North America dominated the diabetic macular edema market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America is expected to be the second most lucrative among all regions, with an attractiveness index of 2.5. APEJ represents the third largest market with a market attractiveness index of 0.4. MEA is expected to remain the least attractive regional market for diabetic macular edema in revenue terms, with an attractiveness index of 0.1 over the forecast period.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Diabetic Macular Edema Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Pipeline Analysis
3.4. Disease Epidemiology
4. North America Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) By Country, 2012-2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016
4.5.1. Anti VEGF Therapies
4.5.1.1. Ranibizumab (Lucentis)
4.5.1.2. Afilbercept (Eylea)
4.5.2. Corticosteroid Therapies
4.5.2.1. Dexamethasone (Ozurdex)
4.5.2.2. Fluocinolone Acetonide (Iluvien)
4.5.3. Other Off-label Drugs
4.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
4.6.1. Anti VEGF Therapies
4.6.1.1. Ranibizumab (Lucentis)
4.6.1.2. Afilbercept (Eylea)
4.6.2. Corticosteroid Therapies
4.6.2.1. Dexamethasone (Ozurdex)
4.6.2.2. Fluocinolone Acetonide (Iluvien)
4.6.3. Other Off-label Drugs
4.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016
4.7.1. Intravitreal Injections
4.7.2. Intravitreal Implants
4.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
4.8.1. Intravitreal Injections
4.8.2. Intravitreal Implants
4.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
4.9.1. Retail Pharmacies
4.9.2. Hospital Pharmacies
4.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
4.10.1. Retail Pharmacies
4.10.2. Hospital Pharmacies
4.11. Market Attractiveness Analysis
4.11.1. By Country
4.11.2. By Product Type
4.11.3. By Product Form
4.11.4. By Distribution Channel
5. Western Europe Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) By Country, 2012-2016
5.3.1. Germany
5.3.2. U.K
5.3.3. France
5.3.4. Italy
5.3.5. Spain
5.3.6. Rest of Western Europe
5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
5.4.1. Germany
5.4.2. U.K
5.4.3. France
5.4.4. Italy
5.4.5. Spain
5.4.6. Rest of Western Europe
5.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016
5.5.1. Anti VEGF Therapies
5.5.1.1. Ranibizumab (Lucentis)
5.5.1.2. Afilbercept (Eylea)
5.5.2. Corticosteroid Therapies
5.5.2.1. Dexamethasone (Ozurdex)
5.5.2.2. Fluocinolone Acetonide (Iluvien)
5.5.3. Other Off-label Drugs
5.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
5.6.1. Anti VEGF Therapies
5.6.1.1. Ranibizumab (Lucentis)
5.6.1.2. Afilbercept (Eylea)
5.6.2. Corticosteroid Therapies
5.6.2.1. Dexamethasone (Ozurdex)
5.6.2.2. Fluocinolone Acetonide (Iluvien)
5.6.3. Other Off-label Drugs
5.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016
5.7.1. Intravitreal Injections
5.7.2. Intravitreal Implants
5.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
5.8.1. Intravitreal Injections
5.8.2. Intravitreal Implants
5.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
5.9.1. Retail Pharmacies
5.9.2. Hospital Pharmacies
5.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
5.10.1. Retail Pharmacies
5.10.2. Hospital Pharmacies
5.11. Market Attractiveness Analysis
5.11.1. By Country
5.11.2. By Product Type
5.11.3. By Product Form
5.11.4. By Distribution Channel
6. Eastern Europe Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) By Country, 2012-2016
6.3.1. Russia
6.3.2. Poland
6.3.3. Rest of Eastern Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
6.4.1. Russia
6.4.2. Poland
6.4.3. Rest of Eastern Europe
6.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016
6.5.1. Anti VEGF Therapies
6.5.1.1. Ranibizumab (Lucentis)
6.5.1.2. Afilbercept (Eylea)
6.5.2. Corticosteroid Therapies
6.5.2.1. Dexamethasone (Ozurdex)
6.5.2.2. Fluocinolone Acetonide (Iluvien)
6.5.3. Other Off-label Drugs
6.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
6.6.1. Anti VEGF Therapies
6.6.1.1. Ranibizumab (Lucentis)
6.6.1.2. Afilbercept (Eylea)
6.6.2. Corticosteroid Therapies
6.6.2.1. Dexamethasone (Ozurdex)
6.6.2.2. Fluocinolone Acetonide (Iluvien)
6.6.3. Other Off-label Drugs
6.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016
6.7.1. Intravitreal Injections
6.7.2. Intravitreal Implants
6.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
6.8.1. Intravitreal Injections
6.8.2. Intravitreal Implants
6.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
6.9.1. Retail Pharmacies
6.9.2. Hospital Pharmacies
6.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
6.10.1. Retail Pharmacies
6.10.2. Hospital Pharmacies
6.11. Market Attractiveness Analysis
6.11.1. By Country
6.11.2. By Product Type
6.11.3. By Product Form
6.11.4. By Distribution Channel
7. Latin America Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Key Regulations
7.3. Regional Market Dynamics
7.3.1. Drivers
7.3.2. Restraints
7.3.3. Trends
7.4. Historical Market Size (US$ Mn) By Country, 2012-2016
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Rest of Latin America
7.5. Market Size (US$ Mn) Forecast By Country, 2017-2027
7.5.1. Brazil
7.5.2. Mexico
7.5.3. Rest of Latin America
7.6. Historical Market Size (US$ Mn) By Product Type, 2012-2016
7.6.1. Anti VEGF Therapies
7.6.1.1. Ranibizumab (Lucentis)
7.6.1.2. Afilbercept (Eylea)
7.6.2. Corticosteroid Therapies
7.6.2.1. Dexamethasone (Ozurdex)
7.6.2.2. Fluocinolone Acetonide (Iluvien)
7.6.3. Other Off-label Drugs
7.7. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
7.7.1. Anti VEGF Therapies
7.7.1.1. Ranibizumab (Lucentis)
7.7.1.2. Afilbercept (Eylea)
7.7.2. Corticosteroid Therapies
7.7.2.1. Dexamethasone (Ozurdex)
7.7.2.2. Fluocinolone Acetonide (Iluvien)
7.7.3. Other Off-label Drugs
7.8. Historical Market Size (US$ Mn) By Product Form, 2012-2016
7.8.1. Intravitreal Injections
7.8.2. Intravitreal Implants
7.9. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
7.9.1. Intravitreal Injections
7.9.2. Intravitreal Implants
7.10. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
7.10.1. Retail Pharmacies
7.10.2. Hospital Pharmacies
7.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
7.11.1. Retail Pharmacies
7.11.2. Hospital Pharmacies
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Product Type
7.12.3. By Product Form
7.12.4. By Distribution Channel
7.13. Key Representative Market Participants
7.14. Key Participants Market Presence (Intensity Map)
8. Asia Pacific Excluding Japan Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) By Country, 2012-2016
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016
8.5.1. Anti VEGF Therapies
8.5.1.1. Ranibizumab (Lucentis)
8.5.1.2. Afilbercept (Eylea)
8.5.2. Corticosteroid Therapies
8.5.2.1. Dexamethasone (Ozurdex)
8.5.2.2. Fluocinolone Acetonide (Iluvien)
8.5.3. Other Off-label Drugs
8.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
8.6.1. Anti VEGF Therapies
8.6.1.1. Ranibizumab (Lucentis)
8.6.1.2. Afilbercept (Eylea)
8.6.2. Corticosteroid Therapies
8.6.2.1. Dexamethasone (Ozurdex)
8.6.2.2. Fluocinolone Acetonide (Iluvien)
8.6.3. Other Off-label Drugs
8.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016
8.7.1. Intravitreal Injections
8.7.2. Intravitreal Implants
8.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
8.8.1. Intravitreal Injections
8.8.2. Intravitreal Implants
8.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
8.9.1. Retail Pharmacies
8.9.2. Hospital Pharmacies
8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
8.10.1. Retail Pharmacies
8.10.2. Hospital Pharmacies
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Product Type
8.11.3. By Product Form
8.11.4. By Distribution Channel
9. Japan Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Regional Market Dynamics
9.2.1. Drivers
9.2.2. Restraints
9.2.3. Trends
9.3. Historical Market Size (US$ Mn) By Product Type, 2012-2016
9.3.1. Anti VEGF Therapies
9.3.1.1. Ranibizumab (Lucentis)
9.3.1.2. Afilbercept (Eylea)
9.3.2. Corticosteroid Therapies
9.3.2.1. Dexamethasone (Ozurdex)
9.3.2.2. Fluocinolone Acetonide (Iluvien)
9.3.3. Other Off-label Drugs
9.4. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
9.4.1. Anti VEGF Therapies
9.4.1.1. Ranibizumab (Lucentis)
9.4.1.2. Afilbercept (Eylea)
9.4.2. Corticosteroid Therapies
9.4.2.1. Dexamethasone (Ozurdex)
9.4.2.2. Fluocinolone Acetonide (Iluvien)
9.4.3. Other Off-label Drugs
9.5. Historical Market Size (US$ Mn) By Product Form, 2012-2016
9.5.1. Intravitreal Injections
9.5.2. Intravitreal Implants
9.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
9.6.1. Intravitreal Injections
9.6.2. Intravitreal Implants
9.7. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
9.7.1. Retail Pharmacies
9.7.2. Hospital Pharmacies
9.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
9.8.1. Retail Pharmacies
9.8.2. Hospital Pharmacies
9.9. Market Attractiveness Analysis
9.9.1. By Product Type
9.9.2. By Product Form
9.9.3. By Distribution Channel
10. Middle East and Africa Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) By Country, 2012-2016
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of Middle East and Africa
10.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of Middle East and Africa
10.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016
10.5.1. Anti VEGF Therapies
10.5.1.1. Ranibizumab (Lucentis)
10.5.1.2. Afilbercept (Eylea)
10.5.2. Corticosteroid Therapies
10.5.2.1. Dexamethasone (Ozurdex)
10.5.2.2. Fluocinolone Acetonide (Iluvien)
10.5.3. Other Off-label Drugs
10.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
10.6.1. Anti VEGF Therapies
10.6.1.1. Ranibizumab (Lucentis)
10.6.1.2. Afilbercept (Eylea)
10.6.2. Corticosteroid Therapies
10.6.2.1. Dexamethasone (Ozurdex)
10.6.2.2. Fluocinolone Acetonide (Iluvien)
10.6.3. Other Off-label Drugs
10.7. Historical Market Size (US$ Mn) By Product Form, 2012-2016
10.7.1. Intravitreal Injections
10.7.2. Intravitreal Implants
10.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
10.8.1. Intravitreal Injections
10.8.2. Intravitreal Implants
10.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
10.9.1. Retail Pharmacies
10.9.2. Hospital Pharmacies
10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
10.10.1. Retail Pharmacies
10.10.2. Hospital Pharmacies
10.11. Market Attractiveness Analysis
10.11.1. By Country
10.11.2. By Product Type
10.11.3. By Product Form
10.11.4. By Distribution Channel
10.12. Key Representative Market Participants
10.13. Key Participants Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
13.1. Market Structure
13.2. Competition Intensity Mapping By Market Taxonomy
13.3. Competition Dashboard
13.4. Key Participants Market Presence (Intensity Map)
13.5. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
13.5.1. Novartis AG
13.5.2. Bayer AG
13.5.3. Allergan Plc.
13.5.4. F. Hoffman-La Roche Ltd.
13.5.5. Alimera Sciences Inc.
13.5.6. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
14. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027 By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) By Region
14.2.1. North America
14.2.2. Western Europe
14.2.3. Eastern Europe
14.2.4. Latin America
14.2.5. Asia Pacific Excluding Japan
14.2.6. Japan
14.2.7. Middle East and Africa
14.3. Market Size (US$ Mn) Forecast By Region
14.3.1. North America
14.3.2. Western Europe
14.3.3. Eastern Europe
14.3.4. Latin America
14.3.5. Asia Pacific Excluding Japan
14.3.6. Japan
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027, By Product Type
15.1. Introduction/Key Finding
15.2. Historical Market Size (US$ Mn) By Product Type, 2012-2016
15.2.1. Anti VEGF Therapies
15.2.1.1. Ranibizumab (Lucentis)
15.2.1.2. Afilbercept (Eylea)
15.2.2. Corticosteroid Therapies
15.2.2.1. Dexamethasone (Ozurdex)
15.2.2.2. Fluocinolone Acetonide (Iluvien)
15.2.3. Other Off-label Drugs
15.3. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
15.3.1. Anti VEGF Therapies
15.3.1.1. Ranibizumab (Lucentis)
15.3.1.2. Afilbercept (Eylea)
15.3.2. Corticosteroid Therapies
15.3.2.1. Dexamethasone (Ozurdex)
15.3.2.2. Fluocinolone Acetonide (Iluvien)
15.3.3. Other Off-label Drugs
15.4. Key Trends / Developments
15.5. Market Attractiveness Analysis By Product Type
16. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027, By Product Form
16.1. Introduction/Key Finding
16.2. Historical Market Size (US$ Mn) By Product Form, 2012-2016
16.2.1. Intravitreal Injections
16.2.2. Intravitreal Implants
16.3. Market Size (US$ Mn) Forecast By Product Type, 2017-2027
16.3.1. Intravitreal Injections
16.3.2. Intravitreal Implants
16.4. Market Attractiveness Analysis By Distribution Channel
17. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027, By Distribution Channel
17.1. Introduction/Key Finding
17.2. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
17.2.1. Retail Pharmacies
17.2.2. Hospital Pharmacies
17.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
17.3.1. Retail Pharmacies
17.3.2. Hospital Pharmacies
17.4. Market Attractiveness Analysis By Distribution Channel
18. Global Diabetic Macular Edema Market Analysis 2012–2016 and Forecast 2017–2027
18.1. Market Size and Y-o-Y Growth
18.2. Absolute $ Opportunity
18.3. Value Chain

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook